Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda debuts with genetically-defined frontotemporal dementia therapy, $44M A round

Sandi Wong, Staff Writer
November 8, 2019 12:43 AM UTC
Updated on Nov 9, 2019 at 2:51 AM UTC

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction.

Arkuda Therapeutics Inc. debuted Thursday with a $44 million series A co-led by Atlas Venture and Pfizer Ventures with participation from Tekla Capital Management, BioInnovation Capital and other, undisclosed investors. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article